<p>Merit Medical Systems, Inc.（納斯達克代碼：MMSI - 獲取免費報告）在週一創下了 52 周的新低，此前 Canaccord Genuity Group 將該股票的目標價從 90.00 美元下調至 85.00 美元。Canaccord Genuity Group 目前對該股票維持買入評級。Merit Medical Systems 的交易最低價為 61.31 美元，最後交易價為 61.89 美元，成交量為 2526188 股。該股票此前收盤價為 62.01 美元。</p>
<p>其他幾位股票研究分析師最近也對該公司發佈了報告。BTIG Research 在 2 月 6 日（星期五）發佈的報告中開始覆蓋 Merit Medical Systems。他們對該股票設定了 “買入” 評級和 107.00 美元的目標價。花旗集團在 4 月 20 日（星期一）的研究報告中重申了對 Merit Medical Systems 股票的 “跑贏大盤” 評級。羅伯特·W·貝爾德在週五的研究報告中對 Merit Medical Systems 股票設定了 83.00 美元的目標價。摩根大通將 Merit Medical Systems 股票的目標價從 95.00 美元下調至 77.00 美元，並在週五的報告中對該股票設定了 “增持” 評級。最後，巴林頓研究在 4 月 20 日（星期一）的研究報告中將 Merit Medical Systems 股票的目標價從 109.00 美元下調至 107.00 美元，並對該股票設定了 “跑贏大盤” 評級。八位研究分析師對該股票給予了買入評級，三位分析師對該股票給予了持有評級。根據 MarketBeat.com 的數據，Merit Medical Systems 目前的平均評級為 “適度買入”，共識目標價為 92.80 美元。</p>
<p>獲取 <strong>Merit Medical Systems</strong> 的提醒：</p>
<p><strong>獲取我們對 Merit Medical Systems 的最新分析</strong></p>
<h2>機構投資者對 Merit Medical Systems 的看法</h2>
<p>機構投資者和對沖基金最近對該公司的持倉進行了調整。洛杉磯資本管理公司在第四季度收購了 Merit Medical Systems 的新頭寸，價值 25000 美元。Maseco LLP 在第四季度收購了 Merit Medical Systems 的股份，價值 26000 美元。Salomon &amp; Ludwin LLC 在第三季度購買了 Merit Medical Systems 的新頭寸，價值約 37000 美元。Torren Management LLC 在第四季度購買了 Merit Medical Systems 的新頭寸，價值約 38000 美元。最後，Covestor Ltd 在第四季度將其在 Merit Medical Systems 的持股增加了 252.6%。Covestor Ltd 現在擁有 469 股該醫療器械供應商的股票，價值 41000 美元，此前在此期間又購買了 336 股。99.66% 的股票由機構投資者和對沖基金持有。</p>
<h2>Merit Medical Systems 股價下跌 8.9%</h2>
<p>該公司的市值為 37 億美元，市盈率為 27.04，市盈增長比率為 1.75，貝塔值為 0.58。該公司的 50 日移動平均線為 70.68 美元，200 日移動平均線為 79.78 美元。公司的流動比率為 5.08，速動比率為 3.46，債務與股本比率為 0.45。</p>
<p>Merit Medical Systems（納斯達克代碼：MMSI - 獲取免費報告）在 4 月 30 日（星期四）最後發佈了其財報。這家醫療器械供應商報告本季度每股收益為 0.94 美元，超出分析師共識預期的 0.84 美元，超出 0.10 美元。該公司本季度的收入為 3.8188 億美元，而共識預期為 3.7759 億美元。Merit Medical Systems 的股本回報率為 13.54%，淨利潤率為 9.03%。與去年同期相比，Merit Medical Systems 的季度收入增長了 7.4%。在去年同期，該公司每股收益為 0.86 美元。Merit Medical Systems 已將其 2026 財年的指導目標設定為每股收益 4.010-4.150 美元。作為一個整體，分析師預計 Merit Medical Systems, Inc.在當前財年將發佈每股收益 3.61 美元。</p>
<h2>Merit Medical Systems 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Merit Medical Systems, Inc.是一家全球製造和銷售廣泛醫療設備的公司，這些設備用於診斷和介入程序。公司的產品組合涵蓋血管通路、引流、栓塞治療和介入腫瘤學設備，以及射頻消融系統和止血解決方案。這些產品為重症監護環境中的醫生和醫院提供服務，並支持多個專業領域的微創治療選擇，包括心臟病學、放射學、腫瘤學、神經學和內窺鏡檢查。</p>
<p>Merit Medical Systems 成立於 1987 年，由 Fred Lampropoulos 創辦，通過有機發展和有針對性的收購不斷壯大，以擴展其技術產品和地理覆蓋範圍。</p>
<h2>另請參閲</h2>
<ul>
<li>我們更看好的五隻股票，優於 Merit Medical Systems</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Merit Medical Systems 嗎？</h2>
<p>在你考慮投資 Merit Medical Systems 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Merit Medical Systems 並不在名單上。</p>
<p>雖然 Merit Medical Systems 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

Merit醫療系統

<p>Merit 醫療系統（NASDAQ:MMSI）在 Canaccord Genuity 將其目標價從 90 美元下調至 85 美元后，達到了 61.31 美元的新 12 個月低點，維持買入評級。該股票交易價格為 61.89 美元，成交量為 2,526,188 股。分析師的評級各不相同，八位推薦買入，三位維持持有。該公司報告第一季度每股收益為 0.94 美元，超出預期，收入為 3.8188 億美元，同比增長 7.4%。Merit 醫療系統的市值為 37 億美元，市場共識目標價為 92.80 美元</p>

<p>Merit Medical Systems, Inc. (NASDAQ:MMSI - Get Free Report) reached a new 52-week low on Monday after Canaccord Genuity Group lowered their price target on the stock from $90.00 to $85.00. Canaccord Genuity Group currently has a buy rating on the stock. Merit Medical Systems traded as low as $61.31 and last traded at $61.89, with a volume of 2526188 shares. The stock had previously closed at $62.01.</p>
<div class="lb-trans"><p>Merit Medical Systems, Inc.（納斯達克代碼：MMSI - 獲取免費報告）在週一創下了 52 周的新低，此前 Canaccord Genuity Group 將該股票的目標價從 90.00 美元下調至 85.00 美元。Canaccord Genuity Group 目前對該股票維持買入評級。Merit Medical Systems 的交易最低價為 61.31 美元，最後交易價為 61.89 美元，成交量為 2526188 股。該股票此前收盤價為 62.01 美元。</p>
</div><p>Several other equities research analysts also recently issued reports on the company. BTIG Research initiated coverage on Merit Medical Systems in a report on Friday, February 6th. They set a &#34;buy&#34; rating and a $107.00 price objective on the stock. Citigroup reiterated an &#34;outperform&#34; rating on shares of Merit Medical Systems in a research note on Monday, April 20th. Robert W. Baird set a $83.00 price target on shares of Merit Medical Systems in a research report on Friday. JPMorgan Chase &amp; Co. cut their price target on shares of Merit Medical Systems from $95.00 to $77.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday. Finally, Barrington Research reduced their price objective on shares of Merit Medical Systems from $109.00 to $107.00 and set an &#34;outperform&#34; rating on the stock in a research note on Monday, April 20th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Merit Medical Systems presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $92.80.</p>
<div class="lb-trans"><p>其他幾位股票研究分析師最近也對該公司發佈了報告。BTIG Research 在 2 月 6 日（星期五）發佈的報告中開始覆蓋 Merit Medical Systems。他們對該股票設定了 “買入” 評級和 107.00 美元的目標價。花旗集團在 4 月 20 日（星期一）的研究報告中重申了對 Merit Medical Systems 股票的 “跑贏大盤” 評級。羅伯特·W·貝爾德在週五的研究報告中對 Merit Medical Systems 股票設定了 83.00 美元的目標價。摩根大通將 Merit Medical Systems 股票的目標價從 95.00 美元下調至 77.00 美元，並在週五的報告中對該股票設定了 “增持” 評級。最後，巴林頓研究在 4 月 20 日（星期一）的研究報告中將 Merit Medical Systems 股票的目標價從 109.00 美元下調至 107.00 美元，並對該股票設定了 “跑贏大盤” 評級。八位研究分析師對該股票給予了買入評級，三位分析師對該股票給予了持有評級。根據 MarketBeat.com 的數據，Merit Medical Systems 目前的平均評級為 “適度買入”，共識目標價為 92.80 美元。</p>
</div><p>Get <strong>Merit Medical Systems</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Merit Medical Systems</strong> 的提醒：</p>
</div><p><strong>Get Our Latest Analysis on Merit Medical Systems</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 Merit Medical Systems 的最新分析</strong></p>
</div><h2>Institutional Investors Weigh In On Merit Medical Systems</h2>
<div class="lb-trans"><h2>機構投資者對 Merit Medical Systems 的看法</h2>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the company. Los Angeles Capital Management LLC acquired a new position in Merit Medical Systems in the fourth quarter worth $25,000. Maseco LLP acquired a new stake in shares of Merit Medical Systems during the fourth quarter worth $26,000. Salomon &amp; Ludwin LLC bought a new position in shares of Merit Medical Systems in the 3rd quarter worth about $37,000. Torren Management LLC bought a new position in shares of Merit Medical Systems in the 4th quarter worth about $38,000. Finally, Covestor Ltd boosted its holdings in shares of Merit Medical Systems by 252.6% in the 4th quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier's stock valued at $41,000 after buying an additional 336 shares during the period. 99.66% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近對該公司的持倉進行了調整。洛杉磯資本管理公司在第四季度收購了 Merit Medical Systems 的新頭寸，價值 25000 美元。Maseco LLP 在第四季度收購了 Merit Medical Systems 的股份，價值 26000 美元。Salomon &amp; Ludwin LLC 在第三季度購買了 Merit Medical Systems 的新頭寸，價值約 37000 美元。Torren Management LLC 在第四季度購買了 Merit Medical Systems 的新頭寸，價值約 38000 美元。最後，Covestor Ltd 在第四季度將其在 Merit Medical Systems 的持股增加了 252.6%。Covestor Ltd 現在擁有 469 股該醫療器械供應商的股票，價值 41000 美元，此前在此期間又購買了 336 股。99.66% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Merit Medical Systems Trading Down 8.9%</h2>
<div class="lb-trans"><h2>Merit Medical Systems 股價下跌 8.9%</h2>
</div><p>The firm has a market cap of $3.70 billion, a P/E ratio of 27.04, a P/E/G ratio of 1.75 and a beta of 0.58. The business's 50-day moving average is $70.68 and its two-hundred day moving average is $79.78. The company has a current ratio of 5.08, a quick ratio of 3.46 and a debt-to-equity ratio of 0.45.</p>
<div class="lb-trans"><p>該公司的市值為 37 億美元，市盈率為 27.04，市盈增長比率為 1.75，貝塔值為 0.58。該公司的 50 日移動平均線為 70.68 美元，200 日移動平均線為 79.78 美元。公司的流動比率為 5.08，速動比率為 3.46，債務與股本比率為 0.45。</p>
</div><p>Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last issued its earnings results on Thursday, April 30th. The medical instruments supplier reported $0.94 EPS for the quarter, beating analysts' consensus estimates of $0.84 by $0.10. The company had revenue of $381.88 million during the quarter, compared to the consensus estimate of $377.59 million. Merit Medical Systems had a return on equity of 13.54% and a net margin of 9.03%.Merit Medical Systems's quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.86 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. As a group, analysts expect that Merit Medical Systems, Inc. will post 3.61 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Merit Medical Systems（納斯達克代碼：MMSI - 獲取免費報告）在 4 月 30 日（星期四）最後發佈了其財報。這家醫療器械供應商報告本季度每股收益為 0.94 美元，超出分析師共識預期的 0.84 美元，超出 0.10 美元。該公司本季度的收入為 3.8188 億美元，而共識預期為 3.7759 億美元。Merit Medical Systems 的股本回報率為 13.54%，淨利潤率為 9.03%。與去年同期相比，Merit Medical Systems 的季度收入增長了 7.4%。在去年同期，該公司每股收益為 0.86 美元。Merit Medical Systems 已將其 2026 財年的指導目標設定為每股收益 4.010-4.150 美元。作為一個整體，分析師預計 Merit Medical Systems, Inc.在當前財年將發佈每股收益 3.61 美元。</p>
</div><h2>Merit Medical Systems Company Profile</h2>
<div class="lb-trans"><h2>Merit Medical Systems 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company's product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.</p>
<div class="lb-trans"><p>Merit Medical Systems, Inc.是一家全球製造和銷售廣泛醫療設備的公司，這些設備用於診斷和介入程序。公司的產品組合涵蓋血管通路、引流、栓塞治療和介入腫瘤學設備，以及射頻消融系統和止血解決方案。這些產品為重症監護環境中的醫生和醫院提供服務，並支持多個專業領域的微創治療選擇，包括心臟病學、放射學、腫瘤學、神經學和內窺鏡檢查。</p>
</div><p>Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.</p>
<div class="lb-trans"><p>Merit Medical Systems 成立於 1987 年，由 Fred Lampropoulos 創辦，通過有機發展和有針對性的收購不斷壯大，以擴展其技術產品和地理覆蓋範圍。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than Merit Medical Systems</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，優於 Merit Medical Systems</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Merit Medical Systems Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Merit Medical Systems 嗎？</h2>
</div><p>Before you consider Merit Medical Systems, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Merit Medical Systems 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merit Medical Systems wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Merit Medical Systems 並不在名單上。</p>
</div><p>While Merit Medical Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Merit Medical Systems 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Merit Medical Systems (NASDAQ:MMSI) Reaches New 12-Month Low Following Analyst Downgrade

Market Beat

花旗

摩根大通

CITIGROUP INC 6.250 NON CUM SER II PFD WI

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Merit 醫療系統（NASDAQ:MMSI）在分析師下調評級後創下新的 12 個月低點